ClinicalTrials.gg
CompletedNCT04168008Updated Nov 3, 2026Results posted

A Peer-Led Intervention to Improve Postpartum Retention in HIV Care

An interventional study of WISH Adherence and WISH Parenting in HIV/AIDS, sponsored by University of Pennsylvania. Completed at 7 sites in United States. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
16 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania — 1 open to participants now, 4 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · University of Pennsylvania.

Enrollment
20th of 30
151 · median 243
Started
2020
with 3 others
No phase
20 of 31
1 open now
Registered
23rd of 31
by date

Among the 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania, this one is the 20th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2020, is one of 20 with no phase, and was the 23rd registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

1 of the 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 16 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Acquired Immunodeficiency Syndrome by University of Pennsylvania, or all of them as a file.
02

Study summary

The purpose of this study is to test the efficacy of a theory-driven peer intervention for pregnant and postpartum women living HIV. The peer intervention is designed to increase self-efficacy, social support, self-regulatory behaviors, and outcome expectancy in order to improve retention in care and viral suppression postpartum. The intervention will consist of face-to-face prenatal educational sessions, starting in early third trimester, and postpartum sessions scheduled up to three months postpartum.

Read the detailed description

Despite significant progress in the reduction of perinatal transmission of HIV, there has been less attention to retaining women living with HIV (WLH) in care in the postpartum period. Retention in care particularly affects black and Hispanic women as they are disproportionately affected by the HIV epidemic in the United States (U.S.). In preliminary work, the investigators used HIV surveillance data from the Philadelphia Department of Public Health to examine the HIV care continuum of 561 women, 78% of whom were black, during pregnancy and up to two years postpartum (2005-2011). Only 38% of women received HIV care within 3 months after delivery, and retention remained poor at 1 (39%) and 2 (25%) years postpartum. Poor maternal retention in care also occurs in Mississippi, Georgia, and New York, demonstrating that this break in the HIV care continuum is widespread. Retaining WLH in care positively impacts their well-being and health postpartum and for years to come, which promotes not only their health but that of their newborns. Therefore, the long-term goal of this study is to decrease HIV disparities by increasing WLH's retention in care in the postpartum period.

Presently, there are a limited number of evidence-based interventions aimed at improving retention in care for WLH. Through a critical review of research literature, the investigators found that interventions to improve retention in care have been implemented in low-resource countries, but studies in high-resource countries are lacking. In sub-Saharan Africa, the use of peers has resulted in significantly higher maternal retention and viral suppression compared to standard of care. Peers are WLH who remained engaged in HIV care postpartum, and provide education and support to WLH in the prenatal and postpartum periods. The investigators also conducted a series of qualitative interviews with WLH in the U.S. to evaluate factors contributing to poor retention in care postpartum, and to assess the acceptability and feasibility of a peer intervention in meeting women's needs. The results showed that women's primary motivation to engage in prenatal care is to keep their infant healthy, but that many of them experience significant life challenges that impede their ability to engage in care postpartum. However, they expressed great interest in receiving support from a peer to motivate sustained engagement in care postpartum.

The investigators propose to test the efficacy of a theory-driven peer intervention, based on the integrated model of health behavior. The peer intervention, Women Involved in Supporting Health (WISH), is designed to increase self-efficacy, social support, self-regulatory behaviors, and outcome expectancy in order to improve retention in care and viral suppression postpartum. The intervention will consist of three face-to-face prenatal sessions, starting in early third trimester, and two face-to-face postpartum sessions scheduled up to three months postpartum. The prenatal sessions focus on knowledge that will address barriers to outcome expectancies and self-efficacy, and the postpartum sessions build on outcome expectancy and knowledge to develop skills tailored to adherence to antiretroviral therapy and engagement in HIV care. Between the sessions, the peer and the WLH will communicate via text messages, phone calls and/or video chat. The randomized controlled trial (RCT) will take place across Center for AIDS Research sites in Philadelphia, the District of Columbia, Atlanta, and Birmingham, where HIV infection rates remain disproportionally high among black and Hispanic women. A total of 260 pregnant WLH will be randomized to either WISH adherence or an attention-matched WISH parenting control group.

The impact of this research will be the development of the first evidence-based peer intervention to address the pressing need to improve postpartum retention in HIV care and viral suppression of WLH in the U.S.

03

Conditions studied

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16 years and older
  • a woman living with in the 2nd or 3rd trimester of pregnancy
  • able to provide including HIPAA authorization to access protected health information
  • able to read and speak English
  • having access to a cell phone

Exclusion criteria

Exclusion Criteria:

  • planning to relocate outside the country within the year following delivery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Adherence

    Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for Antiretroviral therapy (ART) adherence and engagement in HIV care.

    Behavioral: WISH Adherence

  • Active comparator
    Parenting

    Women randomized to the parenting control arm will also attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. The educational sessions will be focused on parenting and baby care.

    Behavioral: WISH Parenting

Interventions

  • BehavioralWISH Adherence

    The educational sessions will consist of an adherence-centered curriculum.

  • BehavioralWISH Parenting

    The educational sessions will focus on parenting and baby care.

06

What researchers measure

Primary outcomes

  1. Retention in Care up to 1 Year Postpartum

    ≥1 visit with an HIV provider in each 6-month interval of the postpartum year with ≥60 days between visits.

    Time frame: Baseline through 1 year after delivery

Secondary outcomes

  1. Viral Suppression up to 1 Year Postpartum

    Viral Load ≤ 200 copies/mL using the last available Viral Load up to 180 days before the end of the postpartum year.

    Time frame: Baseline through 1 year after delivery

07

Results

Posted Nov 3, 2026
Limitations and caveats
Due to multiple factors, we did not reach the original target number of participants. Due to changes from the COVID-19 pandemic we pivoted from in-person to a virtual delivery of the interventions.

Participant flow

From March 2020 to August 2024, 151 participants were randomized. Pregnant women aged ≥16 years receiving prenatal and/or HIV care at participating clinics were recruited during the second or third trimester.

Participant flow — Overall Study
MilestoneAdherenceParenting
Started7774
Completed7261
Not completed513
Withdrew: Lost to follow-up313
Withdrew: Withdrew consent20

Outcome measures

PrimaryRetention in Care up to 1 Year Postpartum

≥1 visit with an HIV provider in each 6-month interval of the postpartum year with ≥60 days between visits.

Time frame:
Baseline through 1 year after delivery
Reported as:
Count of participants · Participants
Retention in Care up to 1 Year Postpartum
ParticipantsAdherenceParenting
Retained4442
Not Retained3332
Statistical analysis
  • Adherence vs Parenting · Regression, Logistic · p = 0.8 · Adjusted odds ratio: 1.09 · 95% CI 0.54 to 2.21Logistic regression adjusted for stratification variables (site and arm), and age, new diagnosis, IPV indicators, categorical depression, and stable housing indicator.
SecondaryViral Suppression up to 1 Year Postpartum

Viral Load ≤ 200 copies/mL using the last available Viral Load up to 180 days before the end of the postpartum year.

Time frame:
Baseline through 1 year after delivery
Reported as:
Count of participants · Participants
Viral Suppression up to 1 Year Postpartum
ParticipantsAdherenceParenting
Suppressed5849
Not Suppressed/Undocumented1925
Statistical analysis
  • Adherence vs Parenting · Regression, Logistic · p = 0.14 · Adjusted odds ratio: 1.83 · 95% CI 0.83 to 4.15Logistic regression adjusted for stratification variables (site and arm), and age, new diagnosis, IPV indicators, categorical depression, and stable housing indicator.

Adverse events

Collected over From enrollment up to 1 year after delivery. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adherence0/77 (0%)0/77 (0%)0/77 (0%)
Parenting0/74 (0%)0/74 (0%)0/74 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AdherenceParentingTotal
Mean30 ± 631 ± 631 ± 6
Sex: Female, Male
Sex: Female, Male(Participants)AdherenceParentingTotal
Female7774151
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AdherenceParentingTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American6661127
White6612
More than one race257
Unknown or Not Reported314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AdherenceParentingTotal
Hispanic or Latino61420
Not Hispanic or Latino7160131
Unknown or Not Reported000
Baseline Retention (One Year Pre-Pregnancy)
Baseline Retention (One Year Pre-Pregnancy)(Participants)AdherenceParentingTotal
Retained282957
Not Retained383270
New Diagnosis111324
08

Study locations

7 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • MedStar Health Research Institute
    Washington D.C., District of Columbia 20010, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Montefiore Medical Center/Albert Einstein College of Medicine
    The Bronx, New York 10466, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Sep 2025, 66 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion. A results delay was requested in Aug 2026.

Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 66 months is above that.

Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2019
First posted
Nov 19, 2019
StartActual
Mar 3, 2020
Primary completionActual
Sep 8, 2025
CompletionActual
Sep 8, 2025
Results delay requested
Aug 27, 2026
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRetention in Care up to 1 year postpartumYear PostpartumTime frame: Baseline through 1 year after delivery
Nov 3, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedViral Suppression up to 1 year postpartumYear PostpartumTime frame: Baseline through 1 year after delivery
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRetention in Care up to 1 year postpartumYear PostpartumTime frame: Baseline through 1 year after delivery
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedViral Suppression up to 1 year postpartumYear PostpartumTime frame: Baseline through 1 year after delivery
    + 2 other changes: verification date and index terms
  2. Oct 9, 2026
    Minor edits only
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04168008
Responsible party
Florence Momplaisir, MD (Assistant Professor, University of Pennsylvania) — Principal investigator
First posted
Nov 19, 2019
Start date
Mar 3, 2020
Primary completion
Sep 8, 2025
Completion
Sep 8, 2025
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion